Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 6/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042835 | 1.00 | ACVR1 (0.42) | ACVR1SPHK2SPHK1CCNE2CDK4 | |
| SCHEMBL5037505 | 0.89 | SPHK2 (0.45) | ACVR1SPHK2SPHK1 | |
| SCHEMBL5037508 | 0.89 | SPHK2 (0.45) | ACVR1SPHK2SPHK1 | |
| SCHEMBL5037485 | 0.85 | ALOX5AP (0.35) | ACVR1SPHK2SPHK1GRM2 | |
| SCHEMBL5037480 | 0.85 | ALOX5AP (0.35) | ACVR1SPHK2SPHK1GRM2 | |
| SCHEMBL5033262 | 0.84 | SPHK2 (0.49) | ACVR1SPHK2SPHK1 | |
| SCHEMBL5033251 | 0.84 | SPHK2 (0.49) | ACVR1SPHK2SPHK1 | |
| SCHEMBL5036061 | 0.81 | NCF1 (0.54) | TLR9TLR7GRM2 | |
| SCHEMBL5037476 | 0.79 | CCNE2 (0.39) | ACVR1CCNE2CDK4CCND1CCNE1 | |
| SCHEMBL5037479 | 0.79 | CCNE2 (0.39) | ACVR1CCNE2CDK4CCND1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | ACVR1 3724/4885SPHK2 3483/4885SPHK1 3433/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | ACVR1 3724/4885SPHK2 3483/4885SPHK1 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.